Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron
Authors:
- Linhui HaoLHLinhui Hao
- Tien-Ying HsiangTHTien-Ying Hsiang
- Ronit R. DalmatRDRonit R. Dalmat
- Renee IretonRIRenee Ireton
- Jennifer F. MortonJMJennifer F. Morton
- Caleb StokesCSCaleb Stokes
- Jason NetlandJNJason Netland
- Malika HaleMHMalika Hale
- Chris ThouvenelCTChris Thouvenel
- Anna WaldAWAnna Wald
- Nicholas M. FrankoNFNicholas M. Franko
- Kristen HudenKHKristen Huden
Open Access
Abstract
New variants of SARS-CoV-2 continue to emerge and evade immunity. We isolated SARS-CoV-2 temporally across the pandemic starting with the first emergence of the virus in the western hemisphere and evaluated the immune escape among variants. A clinic-to-lab viral isolation and characterization pipeline was established to rapidly isolate, sequence, and characterize SARS-CoV-2 variants. A virus neutralization assay was applied to quantitate humoral immunity from infection and/or vaccination. A panel of novel monoclonal antibodies was evaluated for antiviral efficacy. We directly compared all variants, showing that convalescence greater than 5 months post-symptom onset from ancestral virus provides little protection against SARS-CoV-2 variants. Vaccination enhances immunity against viral variants, except for Omicron BA.1, while a three-dose vaccine regimen provides over 50-fold enhanced protection against Omicron BA.1 compared to a two-dose. A novel Mab neutralizes Omicron BA.1 and BA.2 variants better than the clinically approved Mabs, although neither can neutralize Omicron BA.4 or BA.5. Thus, the need remains for continued vaccination-booster efforts, with innovation for vaccine and Mab improvement for broadly neutralizing activity. The usefulness of specific Mab applications links with the window of clinical opportunity when a cognate viral variant is present in the infected population.Keywords
All Related Versions
Funding Information
- National Institutes of Health (AI100625, AI151698)
This publication has 63 references indexed in Scilit:
- Sensitive Recovery of Complete SARS-CoV-2 Genomes from Clinical Samples by Use of Swift Biosciences’ SARS-CoV-2 Multiplex Amplicon Sequencing PanelJournal of Clinical Microbiology, 2020
- An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19bioRxiv, 2020
- Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trialTrials, 2020
- Broad neutralization of SARS-related viruses by human monoclonal antibodiesScience, 2020
- A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiologyNature Microbiology, 2020
- MEGA X: Molecular Evolutionary Genetics Analysis across Computing PlatformsMolecular Biology and Evolution, 2018
- MAFFT online service: multiple sequence alignment, interactive sequence choice and visualizationBriefings in Bioinformatics, 2017
- A SARS-like cluster of circulating bat coronaviruses shows potential for human emergenceNature Medicine, 2015
- aLeaves facilitates on-demand exploration of metazoan gene family trees on MAFFT sequence alignment server with enhanced interactivityNucleic Acids Research, 2013
- An analysis of variance test for normality (complete samples)Biometrika, 1965